Prenatal and Newborn Genetic Testing Market size to exceed USD 26.8 Billion by 2034

Selbyville, DE. - The global prenatal and newborn genetic testing market was estimated at USD 8.1 billion in 2024 and is estimated to grow from USD 9.1 billion in 2025 to USD 26.8 billion by 2034, at a CAGR of 12.8%, according to the latest report published by Global Market Insights Inc.

The increasing prevalence of genetic conditions such as Down syndrome, cystic fibrosis, and spinal muscular atrophy is driving demand for early detection through prenatal and newborn genetic testing. Expectant parents are increasingly seeking reassurance and early intervention options.

Key Insights:

Market Size & Growth:

• 2024 Market Size: USD 8.1 billion
• 2025 Market Size: USD 9.1 billion
• 2034 Forecast Market Size: USD 26.8 billion
• CAGR (2025–2034): 12.8%

Regional Insights:

• Largest Market: North America
• Fastest Growing Market: Asia Pacific
• Emerging Countries: China, India, Brazil, Mexico, South Africa, Indonesia
  

Key Growth Drivers:

1. Advancements in genomic technologies: Rapid innovation in genetic sequencing technologies like next-generation sequencing (NGS), non-invasive prenatal testing (NIPT), and microarray analysis have improved the accuracy, speed, and affordability of genetic testing, expanding its adoption globally.
   
2. Increasing parental awareness and demand for early diagnosis: As public awareness grows around the benefits of early detection and prevention of genetic disorders, more parents are opting for prenatal and newborn screening.
   
3. Government support and newborn screening mandates: Many countries, including the U.S., have implemented mandatory newborn screening programs, with regulatory bodies recommending or requiring testing for a growing panel of genetic conditions.
   
4. Rising maternal age and associated pregnancy risks: With more women choosing to conceive later in life, the risk of chromosomal abnormalities in pregnancies increases.
   
5. Integration of genetic testing into routine prenatal and pediatric care: Healthcare providers are increasingly incorporating genetic screening into standard prenatal checkups and newborn evaluations.
   

Key Players:

• Illumina led the market with over 30% share in 2024.
  
• Some of the top players in this market include LabCorp, Thermo Fisher Scientific, BGI Group, Illumina, and Natera, which together held a 60% share in 2024.
  

Key Challenges

1. Ethical and social concerns: Prenatal and newborn genetic testing raises complex ethical issues, including concerns about selective termination, privacy of genetic information, and potential misuse of results.
   
2. High cost of advanced testing technologies: While the cost of sequencing has decreased over time, advanced genetic tests, especially non-invasive prenatal testing (NIPT) and whole genome sequencing, remain expensive.
   
3. Limited insurance coverage and reimbursement gaps: Many insurance plans do not fully cover advanced genetic testing, especially for low-risk pregnancies.
   
4. Lack of standardization and regulatory oversight: In many markets, there is a lack of standardized guidelines on which conditions should be tested and how results should be interpreted or reported.
   
5. Shortage of genetic counselors: Interpreting genetic test results requires specialized knowledge, and there is a significant shortage of trained genetic counselors.
   

Browse key industry insights spread across 145 pages with 195 market data tables and figures from the report, “Prenatal and Newborn Genetic Testing Market Size - By Product and Services, By Test Type, By Technology, By Application, By End Use, Growth Forecast, 2025 - 2034” in detail, along with the table of contents:

https://www.gminsights.com/industry-analysis/prenatal-and-newborn-genetic-testing-market   

Rising Adoption of Kits and Reagents Segment

The kits and reagents segment held a significant share in 2024, as these consumables are essential for both clinical diagnostics and research workflows. Laboratories and diagnostic centers depend on high-quality, reliable reagents to ensure accurate and reproducible results. As testing volumes grow, driven by increasing demand for early genetic screening, the recurring nature of consumable use continues to boost segment performance.

Increasing Demand for the Prenatal Tests Segment

The prenatal tests segment held a sizeable share in 2024, owing to rising maternal age, increased risk awareness, and strong clinical adoption of non-invasive and invasive testing options. These tests help detect chromosomal abnormalities, genetic mutations, and fetal anomalies early in pregnancy, enabling more informed clinical decision-making. The shift toward first-trimester screening and the inclusion of expanded genetic panels have fueled sustained growth in this segment.

cfDNA to Gain Traction

The cell-free DNA (cfDNA) testing segment held a sustainable share in 2024, driven by a non-invasive, highly accurate method to screen for common chromosomal conditions like trisomy 21, 18, and 13. This method analyzes fetal DNA fragments circulating in maternal blood, reducing the need for invasive procedures like amniocentesis.

North America to Emerge as a Propelling Region

North America prenatal and newborn genetic testing market is poised to grow at a sizeable share in 2024, driven by strong healthcare infrastructure, advanced lab capabilities, and widespread access to genetic services. In the U.S. and Canada, early screening is widely adopted, supported by favorable insurance coverage, regulatory backing, and increasing public awareness. Continued investment in genomic medicine, expansion of NIPT guidelines, and integration of AI-based diagnostic tools are further fueling market growth across this region.

Major players in the prenatal and newborn genetic testing market are Genes2me, Trivitron Healthcare, Retrogen, Aetna, Fulgent Genetics, Eurofins, Illumina, CENTOGENE, Genelab (Clevergene), Thermo Fisher Scientific, Myriad Genetics, Natera, Revvity, LaCAR, BGI Group, BillionToOne, LabCorp, Agilent, and Yourgene Health.

To strengthen their position in the prenatal and newborn genetic testing market, companies are pursuing a mix of innovation-driven and expansion-focused strategies. Many are investing in R&D to develop high-throughput platforms and broaden their test portfolios to cover rare genetic conditions and inherited disorders. Strategic collaborations with hospitals, academic institutions, and technology partners are enabling faster market penetration and access to diverse patient populations.